Examkin

Question

Difficulty: MediumPharmacologic Interventions

A 62-year-old man with a history of type 2 diabetes mellitus and stage 4 chronic kidney disease presents to the emergency department with severe generalized muscle weakness and tingling in his extremities that began earlier today. His home medications include lisinopril, amlodipine, and sitagliptin. His heart rate is 54/min, blood pressure is 112/68 mmHg, and respiratory rate is 18/min. A 12-lead electrocardiogram demonstrates peaked T waves, absent P waves, and a widened QRS complex. A point-of-care basic metabolic panel reveals a serum potassium level of 7.8 mEq/L. The physician decides to immediately begin pharmacologic management.

Arrange the following pharmacologic interventions in the most appropriate sequential order of priority for this patient's acute management.

  1. 1Intravenous calcium gluconate
  2. 2Intravenous regular insulin and 50% dextrose
  3. 3Oral sodium zirconium cyclosilicate

Answer

The correct sequential order of pharmacologic interventions is: 1) Intravenous calcium gluconate, 2) Intravenous regular insulin and 50% dextrose, and 3) Oral sodium zirconium cyclosilicate.
The patient presents with symptomatic severe hyperkalemia (potassium 7.8 mEq/L) exacerbated by an ACE inhibitor (lisinopril) and advanced chronic kidney disease. Most importantly, he has classic severe ECG changes (widened QRS complex, absent P waves, peaked T waves), indicating impending fatal arrhythmia. The foundational protocol for hyperkalemia management is 'Stabilize, Shift, Eliminate'. Intravenous calcium (gluconate or chloride) is always the first step, as it directly antagonizes the membrane effects of hyperkalemia and stabilizes the myocardium within minutes, preventing ventricular fibrillation. Once stabilized, the second step is to shift potassium from the serum into the cells using intravenous insulin (with dextrose) or nebulized albuterol, acting within 15-30 minutes. The final step is total body potassium elimination, achieved through gastrointestinal binders like sodium zirconium cyclosilicate or patiromer, loop diuretics, or hemodialysis. Binders have a delayed onset (hours) and are never used as initial monotherapy for emergent stabilization.

Step-by-Step Solution

1
Administer intravenous calcium gluconate
Stabilization of the cardiac resting membrane potential
The patient has severe hyperkalemia with critical ECG changes (widened QRS), placing him at imminent risk of ventricular fibrillation. Calcium acts immediately (within 1 to 3 minutes) to protect the heart and is the highest priority.
2
Administer intravenous regular insulin and 50% dextrose
Transient shift of potassium from the extracellular to intracellular space
After stabilizing the heart, serum potassium must be lowered rapidly. Insulin drives potassium into cells, effectively lowering serum potassium transiently while awaiting definitive clearance. Dextrose prevents hypoglycemia.
3
Administer oral sodium zirconium cyclosilicate
Definitive removal of potassium from the body via the gastrointestinal tract
Shifting agents are temporary. A definitive elimination strategy is required for sustained reduction in total body potassium. Oral binders are effective but have a delayed onset of action (hours), placing them later in the acute sequence.

Key Concept

In patients with severe hyperkalemia and electrocardiographic changes, pharmacologic management must follow a strict sequence: first stabilize the cardiac membrane (calcium), then shift potassium intracellularly (insulin/dextrose), and finally remove potassium from the body (binders/diuretics/dialysis).
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic